#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Netherton's syndrome Systemic lupus erythematosus VEXAS syndrome Meningococcal immunisation Allogenic stem cell transplantation Oropharyngeal cancer recurrent Growth hormone deficiency Acute myeloid leukaemia recurrent Prophylaxis against transplant rejection Infantile apnoea Blood iron increased Adrenocortical carcinoma Neuroendocrine tumour of the lung Osteosarcoma recurrent Congenital absence of bile ducts More trials…

    Learn about Rare Diseases

    Hepatoblastoma – Life with Disease Medulloblastoma recurrent – Treatment Propionic acidaemia – Diagnostics Gaucher’s disease type III KBG syndrome – Treatment Fabry’s disease – Diagnostics Undifferentiated sarcoma – Basic Information Haemophagocytic lymphohistiocytosis – Life with Disease Lymphatic malformation – Basic Information Atypical haemolytic uraemic syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    [68GA]GA-NOTA-AE105 Agrostis Stolonifera Pollen Tazobactam Sodium Perflutren PICLIDENOSON Oditrasertib Alrefimotide Navtemadlin Lanreotide Abrocitinib Litenimod Sodium Bomedemstat Dalteparin Sodium Iopromide Soticlestat Tramazoline Hydrochloride Cinnarizine FLUCLOXACILLIN SODIUM Fludeoxyglucose (18F) Iclepertin More therapies…

    Learn about Your Condition

    Anal cancer recurrent Seizure Asymptomatic HIV infection Transitional cell carcinoma Paraganglion neoplasm Factor VIII deficiency Post procedural infection Herpes zoster Aneurysm ruptured Hernia repair Pertussis Hypomagnesaemia Indolent systemic mastocytosis Hyperparathyroidism secondary Laryngeal cancer stage II More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Istituto Oncologico Veneto

Istituto Oncologico Veneto

Via Gattamelata 64, Padua, 35128, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

    Recruiting

    3 1
    Belgium France Germany Italy The Netherlands Poland +1

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Epirubicin
    • Goserelin
    • Leuprorelin
    France Germany Italy The Netherlands Spain

  • A Study of Amivantamab and Lazertinib for Adults with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Drugs:
    • Amivantamab
    • Lazertinib
    Belgium Finland France Germany Greece Italy +3

  • A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Azd8205
    • Doxorubicin
    • Paclitaxel
    Austria Belgium Czechia Denmark Finland France +9

  • A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Clear cell renal cell carcinoma
    Investigated Drugs:
    • AB521
    • Placebo
    • Cabozantinib
    Czechia France Germany Hungary Italy The Netherlands +3

  • A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capivasertib
    • RLY-2608
    • Fulvestrant
    Austria Belgium Bulgaria Czechia Denmark France +10

  • Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

    Recruiting

    3 1
    Investigated Diseases:
    • Astrocytoma malignant
    Investigated Drugs:
    • Vorasidenib
    Austria Belgium Czechia France Germany Italy +2

  • A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Belzutifan
    • Cabozantinib
    Austria Belgium Croatia Czechia Denmark France +6

  • Study of XELOX chemotherapy with or without dostarlimab after chemoradiation in patients with locally advanced rectal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Rectal cancer
    Investigated Drugs:
    • Dostarlimab
    Italy

  • Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Capecitabine
    • Carboplatin
    • Gemcitabine
    Austria France Germany Greece Italy Poland +4
Previous Page
1 … 3 4 5 6 7 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!